Source: International Congress 2014 – Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Harlander, M. Zupancic, B. Salobir, M. Tercelj (Ljubljana, Slovenia). Biomarkers in sarcoidois follow-up: Angiotensin-converting enzyme or chitotriosidase?. Eur Respir J 2014; 44: Suppl. 58, 462

Member's Comments

No comment yet.

Related content which might interest you: Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Atypical variants of clinical course of sarcoidosis Source: International Congress 2014 – ILDs 6 Year: 2014 Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Serum levels of sestrin 2 in patients with sarcoidosis Source: International Congress 2014 – ILDs 6 Year: 2014 Cognitive failure in sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Serum angiotensin-converting enzyme activity in lymphangioleiomyomatosis Source: International Congress 2015 – IIPs: orphan Year: 2015 Predictors of cardiovascular events in newly diagnosed patients with sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Neuroendocrine cell hyperplasia (NEHI) and NEHI Syndrome: Lung biopsy necessary? Source: International Congress 2014 – ILDs 4 Year: 2014 Comorbidities associated with sarcoidosis – Results from long-term observational study Source: International Congress 2014 – Sarcoidosis Year: 2014 Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014